These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
206 related articles for article (PubMed ID: 22165692)
1. [Pathophysiological background for incretin therapy: is it capable of more than we think?]. Haluzík M; Urbanová M; Haluzíková D; Trachta P Vnitr Lek; 2011 Nov; 57(11):897-902. PubMed ID: 22165692 [TBL] [Abstract][Full Text] [Related]
2. GLP-1 agonists and dipeptidyl-peptidase IV inhibitors. Gallwitz B Handb Exp Pharmacol; 2011; (203):53-74. PubMed ID: 21484567 [TBL] [Abstract][Full Text] [Related]
3. Incretin based therapies for type 2 diabetes mellitus. Ghosh S; Collier A; Elhadd T; Malik I J Indian Med Assoc; 2008 Jun; 106(6):373-4, 383, 388. PubMed ID: 18839649 [TBL] [Abstract][Full Text] [Related]
4. The future of incretin-based therapy: novel avenues--novel targets. Ahrén B Diabetes Obes Metab; 2011 Oct; 13 Suppl 1():158-66. PubMed ID: 21824270 [TBL] [Abstract][Full Text] [Related]
5. Clinical efficacy of GLP-1 agonists and their place in the diabetes treatment algorithm. Unger J J Am Osteopath Assoc; 2011 Feb; 111(2 Suppl 1):eS2-9. PubMed ID: 21389296 [TBL] [Abstract][Full Text] [Related]
6. Incretin-based therapies for type 2 diabetes mellitus: current status and future prospects. Drab SR Pharmacotherapy; 2010 Jun; 30(6):609-24. PubMed ID: 20500049 [TBL] [Abstract][Full Text] [Related]
8. Incretin-based therapy and type 2 diabetes. Hare KJ; Knop FK Vitam Horm; 2010; 84():389-413. PubMed ID: 21094909 [TBL] [Abstract][Full Text] [Related]
9. Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications. Nauck MA Am J Med; 2011 Jan; 124(1 Suppl):S3-18. PubMed ID: 21194578 [TBL] [Abstract][Full Text] [Related]
10. Clinical pharmacology of incretin therapies for type 2 diabetes mellitus: implications for treatment. Neumiller JJ Clin Ther; 2011 May; 33(5):528-76. PubMed ID: 21665041 [TBL] [Abstract][Full Text] [Related]
11. Differentiating incretin-based therapies for population-based health care. Calabrese D Am J Manag Care; 2011 Mar; 17(2 Suppl):S52-8. PubMed ID: 21517657 [TBL] [Abstract][Full Text] [Related]
12. Incretins and other peptides in the treatment of diabetes. Todd JF; Bloom SR Diabet Med; 2007 Mar; 24(3):223-32. PubMed ID: 17263764 [TBL] [Abstract][Full Text] [Related]
13. [Incretin strategy in the treatment of type 2 diabetes mellitus--DPPIV]. Perusicová J Vnitr Lek; 2007 Sep; 53(9):1005-9. PubMed ID: 18019673 [TBL] [Abstract][Full Text] [Related]
14. Incretin-based therapies and cardiovascular risk. Mannucci E; Dicembrini I Curr Med Res Opin; 2012 May; 28(5):715-21. PubMed ID: 22439700 [TBL] [Abstract][Full Text] [Related]
15. Newly approved and promising antidiabetic agents. Combettes M; Kargar C Therapie; 2007; 62(4):293-310. PubMed ID: 17983555 [TBL] [Abstract][Full Text] [Related]
16. Glycaemic effects of incretins in Type 1 diabetes mellitus: a concise review, with emphasis on studies in humans. Dupre J Regul Pept; 2005 Jun; 128(2):149-57. PubMed ID: 15780434 [TBL] [Abstract][Full Text] [Related]
17. Impact of glucagon-like peptide-1 on endothelial function. Sjöholm A Diabetes Obes Metab; 2009 Dec; 11 Suppl 3():19-25. PubMed ID: 19878258 [TBL] [Abstract][Full Text] [Related]
18. Incretin mimetics and dipeptidyl peptidase-IV inhibitors: potential new therapies for type 2 diabetes mellitus. Triplitt C; Wright A; Chiquette E Pharmacotherapy; 2006 Mar; 26(3):360-74. PubMed ID: 16503716 [TBL] [Abstract][Full Text] [Related]
20. DPP-4 inhibitors and GLP-1 analogues: for whom? Which place for incretins in the management of type 2 diabetic patients? Halimi S Diabetes Metab; 2008 Feb; 34 Suppl 2():S91-5. PubMed ID: 18640591 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]